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Activated neutrophils that infiltrate the liver during severe sepsis lodge themselves in the 
liver’s tiniest blood vessels and cause organ damage. On page  <addart type=”rel” doi=”10.1084/jem.20071765”>915</addart>, McDonald et al. 
examine how neutrophils burrow into the liver and suggest a way to pry them out.
Neutrophil recruitment in response to sepsis-triggering bacterial toxins such as LPS 
unfolds in several stages. In most places in the body, adhesion molecules called selectins 
initially snare neutrophils and help them tether to and roll along blood vessel walls. The cells 
subsequently adhere more firmly through integrins. But because neutrophils do not seem to 
need these molecules to stick to the blood capillaries in the liver, researchers suspected that 
the narrowness of these vessels instead physically traps the neutrophils.
McDonald et al. now provide evidence against this entrapment model by showing 
that neutrophils are snagged by a different adhesion molecule, hyaluronan (HA), which 
they found at high levels in liver vessels. When mice were injected with LPS, neutrophil 
adhesion levels increased 14 fold, although HA levels did not change. The increased 
adhesiveness may be due to an HA-associated protein called SHAP, which increases HA’s affinity for its 
neutrophil cell surface ligand, CD44. SHAP levels on the liver’s capillary walls were increased by LPS treatments.
Disrupting the interaction between CD44 and HA might potentially reverse sepsis; injecting LPS-treated mice with 
an anti-CD44 antibody rapidly detached neutrophils from the liver capillary walls and decreased liver damage. 
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The smallpox virus has been eradicated thanks to 
widespread vaccinations with the vaccinia virus. But 
because live vaccinia virus is used, some vaccine 
recipients, particularly those who are immune 
compromised, have experienced fatal infections. 
Xu et al. (page  <addart  t ype=”rel” do i=”10.1 084/jem .200718 54”>981</addart >) now offer up an alternative 
that might side-step the pitfalls of the old vaccine.
Killed vaccinia virus does not induce antibodies 
against proteins that trigger smallpox, forcing 
researchers to look for alternative strategies. 
Xu et al. considered designing vaccines that target 
virulence proteins that mute the immune response. 
They reasoned that a vaccine that did not include 
the entire virus would be safer, while antibodies 
against virulence proteins, known as immune 
response modifiers (IRMs), would prevent disease 
even if they did not neutralize the virus.
The group now identifies an IRM that is the 
major target of protective antibodies in a 
mouse model of smallpox. This IRM prevents 
the antiviral cytokine interferon-α from 
activating its receptor on immune cells. 
Deletion of the IRM from the mousepox virus, 
the group found, caused a 107-fold decrease in 
its virulence and prevented lethality.
Mice that were injected with the IRM alone 
were protected against a later challenge with the 
wild-type virus. The IRM, the type I interferon 
binding protein, is well-conserved among 
poxviruses that infect mice and men, so the hope 
is that the recombinant IRM protein might be an 
effective poxvirus vaccine for humans as well. 
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T cell receptor genes are created by stitching together three gene segments—
V, D, and J—in different arrangements. But how each set of T cells 
selects its segments is not clear. Xiong et al. (page  <addart type=”rel” doi=”10.1 084/jem.20071275”>929 </addart>) now find that, 
for a set of fetal T cell γδ chains, the appeal of a V segment lies in its 
location relative to the chosen J segment.
In the fetal stage, γδ T cells prefer to use Vγ3 or Vγ4 gene seg-
ments, whereas T cells in the adult thymus instead use Vγ2 or Vγ5. 
Because Vγ3 and Vγ4 are closer to the J segments, Xiong et al. wondered 
whether V segment selection is dictated simply by their position. 
Closer V segments are used preferentially in fetal immunoglobulin 
genes as well, but in that case, proximity correlated with greater tran-
scription and histone acetylation.
To test their new idea, the group engineered mice in which the γ locus 
was altered to replace the Vγ3 segment with a Vγ2 segment. The fetal γδ 
T cells in these mice now included the new Vγ2 segment in preference 
to the more distant Vγ2 segment. They only included more distant gene 
segments if closer segments were deleted. How the nearby segments shut 
out their more remote neighbors is not yet known.
The accessibility of the V segments seemed to be equal across the 
board in fetal cells, as Xiong et al. found that transcription rates didn’t 
predict which segments were used. But in adult γδ T cells, the unused 
segments had lower levels of transcription. Perhaps the gene segments 
used during the fetal stage become inaccessible during adulthood, leaving 
only more distant choices. 
Vγ segments are selected based on their proximity to the J segment during the 
rearrangement of the γδ TCR in fetal stage.
Neutrophils (red) adhere to an adhesion 
molecule called SHAP (green) in liver blood 
capillaries (arrows).